Thomas Blankenstein

ANTIGEN RECOGNIZING CONSTRUCT THAT BINDS SPECIFIC PEPTIDE WITH DETERMINABLE AFFINITY AND T CELL RECEPTOR HAVING ANTIGENIC SPECIFICITY FOR KRAS AS WELL AS CORRESPONDING NUCLEIC ACID SEQUENCE, VECTOR, HOST CELL, PHARMACEUTICAL COMPOSITION AND KIT

A NON-HUMAN MAMMAL COMPRISING IN ITS GENOME AT LEAST TWO HUMAN LEUKOCYTE ANTIGEN (HLA) CLASS I ALLELES, METHODS OF MAKING SUCH MAMMAL AND USES THEREOF

T-CELL RECEPTORS SPECIFIC FOR BOTH RAC1- AND RAC2-DERIVED MUTATED EPITOPES

HIGH AVIDITY ANTIGEN RECOGNIZING CONSTRUCTS

CD5 SPECIFIC T CELL RECEPTOR CELL OR GENE THERAPY

CD22-SPECIFIC T CELL RECEPTORS AND ADOPTIVE T CELL THERAPY FOR TREATMENT OF B CELL MALIGNANCIES

T CELL RECEPTORS FOR TUMOR SPECIFIC PROTEASOME SPLICE VARIANTS AND USES THEREOF

High avidity antigen recognizing constructs

NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME FOR THE TREATMENT OF CANCER AND INFECTIOUS DISEASES

High avidity HPV T-cell receptors

Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1

MULTIPLE TARGET T CELL RECEPTOR

High avidity antigen recognizing constructs

Tumor specific T-cell receptors

GENERATION OF ANTIGEN SPECIFIC T CELLS

MULTIPLE TARGET T CELL RECEPTOR

Generation of antigen specific T cells

Use of Pol III promoters for controlled expression of therapeutic proteins

Epitope-tag surface expressed proteins and nucleic acids thereof

T Cell Line-Based Packaging Cell Line for the Production of Retroviruses by Enriching of Cd3 Expressing Cells